Intech Investment Management LLC Increases Stock Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Intech Investment Management LLC raised its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 29.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,662 shares of the company’s stock after acquiring an additional 9,289 shares during the quarter. Intech Investment Management LLC’s holdings in Pediatrix Medical Group were worth $471,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of MD. Price T Rowe Associates Inc. MD increased its position in Pediatrix Medical Group by 4.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 87,369 shares of the company’s stock valued at $877,000 after purchasing an additional 3,669 shares during the period. Tidal Investments LLC purchased a new position in shares of Pediatrix Medical Group during the first quarter valued at about $442,000. Virtu Financial LLC bought a new position in Pediatrix Medical Group in the first quarter worth about $124,000. Harbor Capital Advisors Inc. lifted its holdings in Pediatrix Medical Group by 48.0% in the second quarter. Harbor Capital Advisors Inc. now owns 54,480 shares of the company’s stock worth $411,000 after buying an additional 17,678 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares in the last quarter. 97.71% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Mizuho raised their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. UBS Group raised their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Truist Financial lifted their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Jefferies Financial Group boosted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Trading Up 0.3 %

NYSE:MD opened at $15.01 on Tuesday. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -4.91, a PEG ratio of 2.12 and a beta of 1.55. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The company’s 50 day moving average price is $13.33 and its 200-day moving average price is $10.28. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% compared to the same quarter last year. During the same period last year, the business posted $0.29 EPS. On average, equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.